Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
Status:
Withdrawn
Trial end date:
2021-06-03
Target enrollment:
Participant gender:
Summary
This is a Phase I/II peptide receptor radiotherapy (PRRT) trial of 177Lu-DOTA-OCTREOTATE in
children and adolescents with neuroendocrine tumors and pheochromocytoma or paraganglioma.